Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1478-6362
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney ; volume:18 ; number:1 ; day:12 ; month:10 ; year:2016 ; pages:1 ; date:12.2016
Arthritis Research & Therapy ; 18, Heft 1 (12.10.2016), 1, 12.2016

Creator
Miner, Jeffrey N.
Contributor
Tan, Philip K.
Hyndman, David
Liu, Sha
Iverson, Cory
Nanavati, Payal
Hagerty, David T.
Manhard, Kimberly
Shen, Zancong
Girardet, Jean-Luc
Yeh, Li-Tain
Terkeltaub, Robert
Quart, Barry
SpringerLink (Online service)

DOI
10.1186/s13075-016-1150-7
URN
urn:nbn:de:1111-201611173168
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
22.08.20025, 6:52 PM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Miner, Jeffrey N.
  • Tan, Philip K.
  • Hyndman, David
  • Liu, Sha
  • Iverson, Cory
  • Nanavati, Payal
  • Hagerty, David T.
  • Manhard, Kimberly
  • Shen, Zancong
  • Girardet, Jean-Luc
  • Yeh, Li-Tain
  • Terkeltaub, Robert
  • Quart, Barry
  • SpringerLink (Online service)

Other Objects (12)

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

Gout and uric acid metabolism

Gout and uric acid metabolism

Variation in serum urate levels in the absence of gout and urate lowering therapy

Variation in serum urate levels in the absence of gout and urate lowering therapy

High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?

High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?

Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout

Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout

Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study

Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study

Adherence with urate-lowering therapies for the treatment of gout

Adherence with urate-lowering therapies for the treatment of gout

Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry

Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry

Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation

Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation

Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase

Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase

Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients

Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients

Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits

Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits

Related objects